A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia

NCT06024876 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Beta-Thalassemia

Interventions

BIOLOGICAL: CS-101

Sponsor

CorrectSequence Therapeutics Co., Ltd

Collaborators

[object Object]